Avadel Pharmaceuticals PLC
AVDLDelisted Feb 12, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001012477
Avadel Pharmaceuticals PLC was delisted on Feb 12, 2026; its insiders filed their last Form 4 on Feb 18, 2026; 208 institutions reported holding it in 13F filings for Q4 2025, worth $1.60B in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Avadel Pharmaceuticals PLC as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +14 vs. Q3 2023
- Shares held
- 56.3M
- +1.94M (+3.6%) vs. Q3 2023
- Total value
- $795.3M
- +$235.9M (+42.2%) vs. Q3 2023
- New holders
- 22
- 34 more added
- Sold out
- 8
- 27 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVDL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $16 |
| Q1 2026 | 2 | $442 |
| Q4 2025 | 208 | $1.60B |
| Q3 2025 | 188 | $1.22B |
| Q2 2025 | 174 | $721.2M |
| Q1 2025 | 177 | $613.0M |
| Q4 2024 | 160 | $837.4M |
| Q3 2024 | 176 | $979.2M |
| Q2 2024 | 156 | $1.04B |
| Q1 2024 | 126 | $1.18B |
| Q4 2023 | 113 | $795.3M |
| Q3 2023 | 99 | $559.4M |
| Q2 2023 | 101 | $856.2M |
| Q1 2023 | 93 | $443.2M |
| Q4 2022 | 83 | $239.5M |
| Q3 2022 | 76 | $157.2M |
| Q2 2022 | 82 | $82.3M |
| Q1 2022 | 81 | $244.5M |
| Q4 2021 | 85 | $287.0M |
| Q3 2021 | 82 | $314.2M |
| Q2 2021 | 80 | $219.1M |
| Q1 2021 | 77 | $294.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Avadel Pharmaceuticals PLC; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tri Locum Partners LP | 839,933 | $11.9M | 5.82% | −143,669−14.6% | Reduced |
| Samsara BioCapital, LLC | 967,527 | $13.7M | 2.13% | 00.0% | Unchanged |
| Morgan Stanley | 991,997 | $14.0M | 0.00% | +554,941+127.0% | Added |
| Tang Capital Management LLC | 1,079,528 | $15.2M | 1.41% | +79,528+8.0% | Added |
| Brandes Investment Partners, LP | 1,533,614 | $21.7M | 0.33% | +84,842+5.9% | Added |
| Cowen and Company, LLC | 1,642,347 | $23.2M | 1.52% | −695,955−29.8% | Reduced |
| Woodline Partners LP | 1,852,412 | $26.2M | 0.29% | −50,431−2.7% | Reduced |
| Wealth Effects LLC | 2,416,326 | $34.1M | 12.83% | +7,037+0.3% | Added |
| Vivo Capital, LLC | 4,096,428 | $57.8M | 4.74% | 00.0% | Unchanged |
| Gendell Jeffrey L | 5,615,350 | $79.3M | 4.31% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 6,751,782 | $95.3M | 0.66% | +2,238,818+49.6% | Added |
| RTW Investments, LP | 6,947,918 | $98.1M | 1.53% | −188,497−2.6% | Reduced |
| Janus Henderson Group PLC | 11,125,330 | $157.1M | 0.09% | +487,023+4.6% | Added |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −163,382−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −104,000−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −53,523−100.0% | Sold out |
| Silverback Asset Management LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −20,047−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −14,582−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −12,091−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −7,587−100.0% | Sold out |